Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotagliflozin and Hydrochlorothiazide DDI Study
NCT03387657Phase 1Completed
- Sponsor
- Sanofi
- Start
- Jan 2018
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sotagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Area under the plasma concentration versus time curve during a dosing interval. Started Jan 2018; status: completed.
02
Drugs
sotagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03387657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387657.